TY - JOUR
T1 - The Safety, Tolerability, and Efficacy of DL-Lactic Acid Syrup (Tonsitin) in Children With Recurrent Tonsillitis
T2 - A Pilot Study
AU - Taha, Ahmed
AU - Yeheskeli, Eyal
AU - Gavriel, Haim
AU - Berkovitch, Matitiahu
AU - Mizrakli, Yuval
AU - Shlamkovitch, Natan
AU - Kohn, Elkana
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/10
Y1 - 2024/10
N2 - To evaluate Tonsitin (10% DL-lactic acid) safety, tolerability, and efficacy, as a treatment for recurrent tonsillitis (RT) in children. This is a clinical prospective, randomized, double blind pilot study, to evaluate the safety, tolerability and efficacy of Tonsitin in healthy children with RT. Safety evaluated in terms of adverse events (AEs), tolerability in terms of compliance, and efficacy in terms of tonsils’ size and frequency of tonsillitis, and quality of life. The study included 51 children. The treatment regimen was tolerable among the participants. Six children experienced AEs, but mostly mild. Tonsil size declined in both groups, but these results did not reach statistical significance. Tonsillitis episodes’ frequencies were random and not significant. Tonsitin treatment was found to be feasible in the clinical setup and was well tolerated, and appears to be safe. Study efficacy results did not reach statistical significance.
AB - To evaluate Tonsitin (10% DL-lactic acid) safety, tolerability, and efficacy, as a treatment for recurrent tonsillitis (RT) in children. This is a clinical prospective, randomized, double blind pilot study, to evaluate the safety, tolerability and efficacy of Tonsitin in healthy children with RT. Safety evaluated in terms of adverse events (AEs), tolerability in terms of compliance, and efficacy in terms of tonsils’ size and frequency of tonsillitis, and quality of life. The study included 51 children. The treatment regimen was tolerable among the participants. Six children experienced AEs, but mostly mild. Tonsil size declined in both groups, but these results did not reach statistical significance. Tonsillitis episodes’ frequencies were random and not significant. Tonsitin treatment was found to be feasible in the clinical setup and was well tolerated, and appears to be safe. Study efficacy results did not reach statistical significance.
KW - 10% DL-lactic acid syrup (Tonsitin)
KW - recurrent tonsillitis
KW - tonsillar hypertrophy
UR - http://www.scopus.com/inward/record.url?scp=85182210915&partnerID=8YFLogxK
U2 - 10.1177/00099228231222317
DO - 10.1177/00099228231222317
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38205711
AN - SCOPUS:85182210915
SN - 0009-9228
VL - 63
SP - 1395
EP - 1405
JO - Clinical Pediatrics
JF - Clinical Pediatrics
IS - 10
ER -